B 2067 2
Alternative Names: B-2067-2Latest Information Update: 25 Jul 2022
At a glance
- Originator Tasly Biopharmaceuticals
- Class Antianaemics; Antibodies; Eye disorder therapies
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Atypical Haemolytic Uraemic Syndrome; Autoimmune disorders; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria